Izere Salomon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Izere Salomon has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
Khaled Moghib
Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt
7 shared publications- Kanza Farhan
Jinnah Sindh Medical University, Karachi, Pakistan
6 shared publications - Khaled Moghib
Faculty of Medicine, Kasr Al-Ainy, Cairo University
6 shared publications - Muhammad Burhan Tariq
Sindh Medical College Jinnah Sindh Medical University Karachi Pakistan
5 shared publications Abdallah Abunamoos
University of Jordan, Amman, Jordan
3 shared publications- Muhannad Wael
Hadassah Medical Center, Jerusalem, Palestine
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 54 (1) , 234
Socioeconomic inequality and factors associated with deworming service receipt among preschool-aged children (12–59 months) in sub-Saharan Africa: a multicountry demographic and health surveys analysis (2006–2024)
- 9 November 2026
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 54 (1) , 234
Open AccessSocioeconomic inequality and factors associated with deworming service receipt among preschool-aged children (12–59 months) in sub-Saharan Africa: a multicountry demographic and health surveys analysis (2006–2024)
- Open Access
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Nephrology
- Vol. 6, 1908272
Serum uric acid in pediatric metabolic assessment: the scientific rationale for routine screening and the urgent need for age- and sex-specific diagnostic thresholds
Serum uric acid (SUA) is the terminal product of purine catabolism in humans, generated through the sequential action of xanthine oxidoreductase on hypoxanthine and xanthine (Figure 1). Classically, elevation above accepted adult thresholds of 416 μmol/L (7.0 mg/dL) in males and 357 μmol/L(6.0 mg/dL) in females defines hyperuricemia and confers risk for gouty arthritis and nephrolithiasis. Over the past two decades, a growing body of epidemiological, pathophysiological, and interventional evidence has substantially broadened this picture. Elevated SUA is now consistently associated with hypertension, insulin resistance, metabolic syndrome, chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease (MASLD) in both adults and children, though the nature and direction of these relationships vary across outcomes and, in several domains, causality remains an active area of scientific debate. [1][2][3] Serum uric acid homeostasis reflects the balance between purine metabolism, dietary and metabolic influences, and renal excretion. Hyperuricemia may result from increased uric acid production, reduced renal clearance, or both. In children, obesity, chronic kidney disease, fructose-rich diets, purine-rich foods, malignancies associated with increased cell turnover, and tumor lysis syndrome are among the principal contributors, as shown in Figure 1. These mechanisms converge on hepatic purine metabolism, where xanthine oxidase catalyzes the final steps leading to uric acid formation, providing the biological rationale for the use of xanthine oxidase inhibitors and uricase-based therapies in selected clinical settings. Despite this evidence, SUA measurement remains largely absent from the routine pediatric metabolic panel in most international clinical guidelines. Its use in children is predominantly restricted to acute clinical contexts such as oncological tumor lysis syndrome and overt gouty arthritis endpoints that represent the extreme and late expression of what is often a prolonged subclinical process.Population data indicate that hyperuricemia affects a substantial and growing proportion of children globally, driven by the parallel epidemics of childhood obesity and increased dietary fructose consumption. 5,6 A pooled analysis of over 54,000 Chinese children and adolescents documented a hyperuricemia prevalence of 24.8% in 2016-2019, up from 16.7% in the preceding survey cycle. 5 , and prevalence estimates exceeding 50% have been reported in obese pediatric cohorts in some regions. 6 A critical obstacle to clinical action is the absence of validated, age-and sex-specific reference intervals for SUA in children. The adult diagnostic thresholds currently in use are not derived from pediatric populations, do not account for the progressive rise in SUA across childhood, and do not reflect the sex divergence that emerges only after puberty. 7,8 Applying fixed adult cut-offs to children of all ages and both sexes results in systematic misclassification, contributing in part to the clinical inertia that has surrounded this biomarker in pediatric practice.The physiological basis of this age-and sex-dependent variation is well characterized and merits explicit statement before the epidemiological evidence is reviewed. SUA is relatively low in infancy, typically 2.2-2.5 mg/dL, reflecting a fractional excretion of uric acid (FE-UA) that exceeds 10% in the first months of life; FE-UA declines to approximately 8% by one year of age, after which SUA in most children stabilizes in the range of 3.5-4.5 mg/dL. 9,10 Renal tubular urate handling continues to mature throughout childhood, and after puberty, FE-UA falls further in boys but not in girls, resulting in the higher SUA concentrations characteristic of adolescent males relative to females. 10 These maturational changes in renal urate handling, superimposed on the progressive rise in body weight and dietary purine intake across childhood, together explain why no single adult-derived threshold can be validly applied at any point across the pediatric age range, and why the age-and sex-stratified data reviewed below are indispensable rather than merely preferable. This editorial argues that the cumulative evidence now supports incorporating SUA into routine pediatric metabolic screening in defined high-risk groups. In advancing this argument, we deliberately separate two distinct claims that are frequently conflated in the literature: SUA as a validated risk marker, for which the observational, mechanistic, and, in the case of hypertension, interventional evidence is now substantial, and SUA as a clinically actionable screening parameter with demonstrated downstream benefit, for which prospective screening-outcome trials in children do not yet exist. The recommendations that follow rest on the former claim; they should not be read as asserting the latter, and we return to this distinction explicitly before presenting the proposed framework. We review the epidemiological and interventional evidence linking elevated SUA to pediatric cardiometabolic and renal outcomes, examine existing data on age-and sex-specific reference intervals, consider the global applicability and practical implications of screening, and propose a minimum framework for clinical implementation.Estimating the true prevalence of childhood hyperuricemia is complicated by the lack of a universally accepted pediatric definition, but available data consistently indicate that elevated SUA is common and rising. Rao et al. (2022), pooling data from 11 population-based Chinese studies comprising 54,580 participants aged 3-19 years, reported a prevalence that increased markedly with age from 3.7% at ages 3-5 years to 35.5% at ages 12-15 years and with weight status, reaching 64.5% among children with extreme obesity. 5 A multicenter European clinical series of 13,890 children found hyperuricemia in 12.6% of the overall pediatric population, with...
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Nephrology
- Vol. 6, 1908272
Open AccessSerum uric acid in pediatric metabolic assessment: the scientific rationale for routine screening and the urgent need for age- and sex-specific diagnostic thresholds
Serum uric acid (SUA) is the terminal product of purine catabolism in humans, generated through the sequential action of xanthine oxidoreductase on hypoxanthine and xanthine (Figure 1). Classically, elevation above accepted adult thresholds of 416 μmol/L (7.0 mg/dL) in males and 357 μmol/L(6.0 mg/dL) in females defines hyperuricemia and confers risk for gouty arthritis and nephrolithiasis. Over the past two decades, a growing body of epidemiological, pathophysiological, and interventional evidence has substantially broadened this picture. Elevated SUA is now consistently associated with hypertension, insulin resistance, metabolic syndrome, chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease (MASLD) in both adults and children, though the nature and direction of these relationships vary across outcomes and, in several domains, causality remains an active area of scientific debate. [1][2][3] Serum uric acid homeostasis reflects the balance between purine metabolism, dietary and metabolic influences, and renal excretion. Hyperuricemia may result from increased uric acid production, reduced renal clearance, or both. In children, obesity, chronic kidney disease, fructose-rich diets, purine-rich foods, malignancies associated with increased cell turnover, and tumor lysis syndrome are among the principal contributors, as shown in Figure 1. These mechanisms converge on hepatic purine metabolism, where xanthine oxidase catalyzes the final steps leading to uric acid formation, providing the biological rationale for the use of xanthine oxidase inhibitors and uricase-based therapies in selected clinical settings. Despite this evidence, SUA measurement remains largely absent from the routine pediatric metabolic panel in most international clinical guidelines. Its use in children is predominantly restricted to acute clinical contexts such as oncological tumor lysis syndrome and overt gouty arthritis endpoints that represent the extreme and late expression of what is often a prolonged subclinical process.Population data indicate that hyperuricemia affects a substantial and growing proportion of children globally, driven by the parallel epidemics of childhood obesity and increased dietary fructose consumption. 5,6 A pooled analysis of over 54,000 Chinese children and adolescents documented a hyperuricemia prevalence of 24.8% in 2016-2019, up from 16.7% in the preceding survey cycle. 5 , and prevalence estimates exceeding 50% have been reported in obese pediatric cohorts in some regions. 6 A critical obstacle to clinical action is the absence of validated, age-and sex-specific reference intervals for SUA in children. The adult diagnostic thresholds currently in use are not derived from pediatric populations, do not account for the progressive rise in SUA across childhood, and do not reflect the sex divergence that emerges only after puberty. 7,8 Applying fixed adult cut-offs to children of all ages and both sexes results in systematic misclassification, contributing in part to the clinical inertia that has surrounded this biomarker in pediatric practice.The physiological basis of this age-and sex-dependent variation is well characterized and merits explicit statement before the epidemiological evidence is reviewed. SUA is relatively low in infancy, typically 2.2-2.5 mg/dL, reflecting a fractional excretion of uric acid (FE-UA) that exceeds 10% in the first months of life; FE-UA declines to approximately 8% by one year of age, after which SUA in most children stabilizes in the range of 3.5-4.5 mg/dL. 9,10 Renal tubular urate handling continues to mature throughout childhood, and after puberty, FE-UA falls further in boys but not in girls, resulting in the higher SUA concentrations characteristic of adolescent males relative to females. 10 These maturational changes in renal urate handling, superimposed on the progressive rise in body weight and dietary purine intake across childhood, together explain why no single adult-derived threshold can be validly applied at any point across the pediatric age range, and why the age-and sex-stratified data reviewed below are indispensable rather than merely preferable. This editorial argues that the cumulative evidence now supports incorporating SUA into routine pediatric metabolic screening in defined high-risk groups. In advancing this argument, we deliberately separate two distinct claims that are frequently conflated in the literature: SUA as a validated risk marker, for which the observational, mechanistic, and, in the case of hypertension, interventional evidence is now substantial, and SUA as a clinically actionable screening parameter with demonstrated downstream benefit, for which prospective screening-outcome trials in children do not yet exist. The recommendations that follow rest on the former claim; they should not be read as asserting the latter, and we return to this distinction explicitly before presenting the proposed framework. We review the epidemiological and interventional evidence linking elevated SUA to pediatric cardiometabolic and renal outcomes, examine existing data on age-and sex-specific reference intervals, consider the global applicability and practical implications of screening, and propose a minimum framework for clinical implementation.Estimating the true prevalence of childhood hyperuricemia is complicated by the lack of a universally accepted pediatric definition, but available data consistently indicate that elevated SUA is common and rising. Rao et al. (2022), pooling data from 11 population-based Chinese studies comprising 54,580 participants aged 3-19 years, reported a prevalence that increased markedly with age from 3.7% at ages 3-5 years to 35.5% at ages 12-15 years and with weight status, reaching 64.5% among children with extreme obesity. 5 A multicenter European clinical series of 13,890 children found hyperuricemia in 12.6% of the overall pediatric population, with...
- Open Access
- 7 August 2026
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 19 (1) , 201
An atypical presentation of Lemierre syndrome in a child with nephrotic syndrome: a case report and literature review
- 7 August 2026
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 19 (1) , 201
Open AccessAn atypical presentation of Lemierre syndrome in a child with nephrotic syndrome: a case report and literature review
- Open Access
- 15 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3541-3555
Efficacy and safety of risankizumab in moderate to severe psoriasis: an updated systematic review and meta-analysis
Background: Risankizumab, a selective IL-23 inhibitor, has emerged as a promising therapeutic agent for moderate-to-severe plaque psoriasis. This study aims to systematically assess its efficacy and safety through an updated meta-analysis of randomized controlled trials (RCTs). Methods: A comprehensive literature search of PubMed/MEDLINE, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov was conducted from their inception to 15 April 2025 for RCTs comparing risankizumab with placebo or active comparators in adults with moderate-to-severe psoriasis. Data were pooled using random-effects models (RevMan 5.4), and heterogeneity was assessed using I 2 statistics. The Cochrane Risk of Bias Tool 2 (RoB 2) was utilized for risk of bias assessment of each included RCT. The forest plots were generated using risk ratios (RRs) with 95% confidence intervals (CIs). Results: Eleven RCTs ( n = 2664 patients) were included in the study. Risankizumab showed significantly greater efficacy than placebo for PASI 75 (OR: 23.93, 95% CI: 7.80–73.41), PASI 90 (OR: 18.11, 95% CI: 5.03–65.24), and PASI 100 (OR: 30.31, 95% CI: 12.36–74.34). Compared to active comparators (ustekinumab and adalimumab), risankizumab demonstrated a superior PASI 90 response (OR 3.40, 95% CI: 2.32–4.96). Quality of life (DLQI) improved significantly (OR: 31.53, 95% CI: 19.46–51.09). No increased risk of SAEs was observed (OR: 0.71, 95% CI: 0.33–1.54), although the infection risk was slightly elevated (OR: 1.38, 95% CI: 0.87–2.18). Conclusion: This meta-analysis confirms the superiority of risankizumab over placebo and other biologics in achieving complete or near-complete skin clearance, with a favorable safety profile. These findings suggest that risankizumab is a first-line biologic agent for moderate-to-severe plaque psoriasis, although infection monitoring remains warranted.
- 15 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3541-3555
Open AccessEfficacy and safety of risankizumab in moderate to severe psoriasis: an updated systematic review and meta-analysis
Background: Risankizumab, a selective IL-23 inhibitor, has emerged as a promising therapeutic agent for moderate-to-severe plaque psoriasis. This study aims to systematically assess its efficacy and safety through an updated meta-analysis of randomized controlled trials (RCTs). Methods: A comprehensive literature search of PubMed/MEDLINE, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov was conducted from their inception to 15 April 2025 for RCTs comparing risankizumab with placebo or active comparators in adults with moderate-to-severe psoriasis. Data were pooled using random-effects models (RevMan 5.4), and heterogeneity was assessed using I 2 statistics. The Cochrane Risk of Bias Tool 2 (RoB 2) was utilized for risk of bias assessment of each included RCT. The forest plots were generated using risk ratios (RRs) with 95% confidence intervals (CIs). Results: Eleven RCTs ( n = 2664 patients) were included in the study. Risankizumab showed significantly greater efficacy than placebo for PASI 75 (OR: 23.93, 95% CI: 7.80–73.41), PASI 90 (OR: 18.11, 95% CI: 5.03–65.24), and PASI 100 (OR: 30.31, 95% CI: 12.36–74.34). Compared to active comparators (ustekinumab and adalimumab), risankizumab demonstrated a superior PASI 90 response (OR 3.40, 95% CI: 2.32–4.96). Quality of life (DLQI) improved significantly (OR: 31.53, 95% CI: 19.46–51.09). No increased risk of SAEs was observed (OR: 0.71, 95% CI: 0.33–1.54), although the infection risk was slightly elevated (OR: 1.38, 95% CI: 0.87–2.18). Conclusion: This meta-analysis confirms the superiority of risankizumab over placebo and other biologics in achieving complete or near-complete skin clearance, with a favorable safety profile. These findings suggest that risankizumab is a first-line biologic agent for moderate-to-severe plaque psoriasis, although infection monitoring remains warranted.
- Open Access
- 20 April 2026
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 19 (1)
Operationalizing preparedness: bridging the “Know-Do” gap in Rwanda’s infectious disease policy
- 20 April 2026
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 19 (1)
Open AccessOperationalizing preparedness: bridging the “Know-Do” gap in Rwanda’s infectious disease policy
- Open Access
- 2 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (5) , 2725-2727
Vimkunya vaccine: a breakthrough in combating chikungunya
The chikungunya virus (CHIKV) is a serious global health concern that is transmitted by Aedes mosquitoes and causes fever, rash, headaches, arthralgia, and fatigue. In 2024, there were approximately 620 000 cases reported and 213 fatalities across the world. In February, Vimkunya (PXVX0317), a virus-like particle vaccine, which is safer than the live-attenuated IXCHIQ vaccine, was approved by the FDA. The Vimkunya has recombinant structural proteins that induce strong neutralizing antibody responses without allowing the virus to replicate. Clinical trials have demonstrated immunogenicity, with a seroresponse rate of ≥87% in older adults and 98% in younger individuals. There were only mild to moderate adverse effects, like headaches, muscle pain, and pain at the injection site, were reported. Vimkunya is a potential approach to lessen the impact of chikungunya and prevent recurrent outbreaks. It has proven to be effective in all age groups, elicits a sustained immune response, and has demonstrated a safer profile in trials. Strategies for fair distribution and ongoing monitoring will be essential for the impact on public health.
- 2 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (5) , 2725-2727
Open AccessVimkunya vaccine: a breakthrough in combating chikungunya
The chikungunya virus (CHIKV) is a serious global health concern that is transmitted by Aedes mosquitoes and causes fever, rash, headaches, arthralgia, and fatigue. In 2024, there were approximately 620 000 cases reported and 213 fatalities across the world. In February, Vimkunya (PXVX0317), a virus-like particle vaccine, which is safer than the live-attenuated IXCHIQ vaccine, was approved by the FDA. The Vimkunya has recombinant structural proteins that induce strong neutralizing antibody responses without allowing the virus to replicate. Clinical trials have demonstrated immunogenicity, with a seroresponse rate of ≥87% in older adults and 98% in younger individuals. There were only mild to moderate adverse effects, like headaches, muscle pain, and pain at the injection site, were reported. Vimkunya is a potential approach to lessen the impact of chikungunya and prevent recurrent outbreaks. It has proven to be effective in all age groups, elicits a sustained immune response, and has demonstrated a safer profile in trials. Strategies for fair distribution and ongoing monitoring will be essential for the impact on public health.
- Open Access
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1784458
Forgotten left bronchial foreign body spontaneously expelled during chest physiotherapy: a pediatric case report
Foreign body aspiration is common in pediatric setting and in chronic cases such patients often present with clinical features similar to infective respiratory etiologies. This is the case of a forgotten left bronchial foreign body in a 5-year-old girl, who presented with worsening of recurrent cough and fever. She was previously being treated as case of bronchial asthma and foreign body was missed on the imaging as well. It was subsequently expelled by chest physiotherapy. The case highlights the importance of having foreign body aspiration (FBA) as a differential in cases of chronic cough, even without any history of choking, to avoid diagnostic challenge. Moreover, spontaneous expulsion of foreign body was incidental clinical event and is not substitute for standard clinical care.
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1784458
Open AccessForgotten left bronchial foreign body spontaneously expelled during chest physiotherapy: a pediatric case report
Foreign body aspiration is common in pediatric setting and in chronic cases such patients often present with clinical features similar to infective respiratory etiologies. This is the case of a forgotten left bronchial foreign body in a 5-year-old girl, who presented with worsening of recurrent cough and fever. She was previously being treated as case of bronchial asthma and foreign body was missed on the imaging as well. It was subsequently expelled by chest physiotherapy. The case highlights the importance of having foreign body aspiration (FBA) as a differential in cases of chronic cough, even without any history of choking, to avoid diagnostic challenge. Moreover, spontaneous expulsion of foreign body was incidental clinical event and is not substitute for standard clinical care.
- Open Access
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1790444
Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis
Background: The safety and efficacy of Chimeric Antigen Receptor (CAR) T-cell therapy in Central Nervous System Lymphoma (CNSL) remain uncertain, given the limited representation of CNS involvement in pivotal CAR T-cell trials. This meta-analysis synthesized data from studies evaluating outcomes in both primary (PCNSL) and secondary CNS lymphoma (SCNSL) cohorts treated with CART. Methods: A comprehensive search was performed across PubMed, Embase, and clinical registries up to October 2025. Studies reporting efficacy or toxicity outcomes in CNSL following CD19-targeted CART therapy were included. Proportions were stabilized using the Freeman-Tukey double arcsine transformation and pooled using inverse variance weighting. Between-study heterogeneity was estimated with the DerSimonian-Laird method, and τ² confidence intervals were calculated via the Jackson approach. Publication bias was assessed using Egger’s regression. Subgroup and multiple meta-regression analyses evaluated moderators including CNS category (PCNSL vs SCNSL) and publication year. Results: Data from thirty-eight studies were meta-analyzed. The pooled overall response rate (ORR) was 0.75 [95% CI: 0.70–0.79] with moderate-to-substantial heterogeneity (I² = 53.3%). Complete response (CR) rate was 0.52 [0.46–0.58], and partial response (PR) rate 0.18 [0.14–0.22]. No significant publication bias was detected (Egger’s p = 0.39 for ORR). Meta-regression indicated no significant effect of publication year or lymphoma subtype on response. Cytokine Release Syndrome (CRS) occurred in 83.5% [79.0–88.0], with grade ≥3 CRS in 5.77% [3.0–9.0]. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was reported in 44.9% [36.0–54.0], with severe (grade ≥3) events in 17.4% [12.0–23.0]. Heterogeneity was substantial for ICANS (I² = 84.2%) but moderate for CRS (I² = 64.3%). Conclusions: CART therapy achieves robust response rates in CNS lymphoma, with efficacy comparable between PCNSL and SCNSL. Neurotoxicity remains frequent but manageable, and severe CRS events are infrequent. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251070033.
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1790444
Open AccessSafety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis
Background: The safety and efficacy of Chimeric Antigen Receptor (CAR) T-cell therapy in Central Nervous System Lymphoma (CNSL) remain uncertain, given the limited representation of CNS involvement in pivotal CAR T-cell trials. This meta-analysis synthesized data from studies evaluating outcomes in both primary (PCNSL) and secondary CNS lymphoma (SCNSL) cohorts treated with CART. Methods: A comprehensive search was performed across PubMed, Embase, and clinical registries up to October 2025. Studies reporting efficacy or toxicity outcomes in CNSL following CD19-targeted CART therapy were included. Proportions were stabilized using the Freeman-Tukey double arcsine transformation and pooled using inverse variance weighting. Between-study heterogeneity was estimated with the DerSimonian-Laird method, and τ² confidence intervals were calculated via the Jackson approach. Publication bias was assessed using Egger’s regression. Subgroup and multiple meta-regression analyses evaluated moderators including CNS category (PCNSL vs SCNSL) and publication year. Results: Data from thirty-eight studies were meta-analyzed. The pooled overall response rate (ORR) was 0.75 [95% CI: 0.70–0.79] with moderate-to-substantial heterogeneity (I² = 53.3%). Complete response (CR) rate was 0.52 [0.46–0.58], and partial response (PR) rate 0.18 [0.14–0.22]. No significant publication bias was detected (Egger’s p = 0.39 for ORR). Meta-regression indicated no significant effect of publication year or lymphoma subtype on response. Cytokine Release Syndrome (CRS) occurred in 83.5% [79.0–88.0], with grade ≥3 CRS in 5.77% [3.0–9.0]. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was reported in 44.9% [36.0–54.0], with severe (grade ≥3) events in 17.4% [12.0–23.0]. Heterogeneity was substantial for ICANS (I² = 84.2%) but moderate for CRS (I² = 64.3%). Conclusions: CART therapy achieves robust response rates in CNS lymphoma, with efficacy comparable between PCNSL and SCNSL. Neurotoxicity remains frequent but manageable, and severe CRS events are infrequent. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251070033.
- Open Access
- 20 March 2026
- Published by Frontiers Media SA in Frontiers in Digital Health
- Vol. 8, 1783456
Technology-driven diabetes care: innovation without equity?
Diabetes mellitus type 1, commonly known as type 1 diabetes (T1D), is an autoimmune disease that occurs when the body's immune system destroys insulin-producing β-cells in the pancreas, leading to little or no endogenous insulin production (5). People with T1D (often diagnosed in childhood) require lifelong insulin therapy to remain alive (5). In contrast, Diabetes mellitus type 2, also commonly known as type 2 diabetes (T2D), is a form of diabetes mellitus characterized by insulin resistance and relative insulin deficiency (5). Most patients with T2D are initially managed with lifestyle changes and oral medications, with insulin reserved for later stages or in special situations. T2D is far more common than T1D, accounting for approximately 90-95% of all diabetes cases(5), and is strongly associated with obesity and aging.These distinctions affect technology use; advanced devices such as insulin pumps and automated "artificial pancreas" systems have been developed primarily for insulin-dependent patients, whereas T2D care more often uses glucose meters, CGMs, telemedicine, and mobile apps to support lifestyle and medication adherence. Notably, digital interventions have been shown to improve glycemic control in both T1 and T2Ds (6), but access and uptake have not been equal in the largely non-insulin-dependent T2 population.In theory, these advancements can reduce complications and costs. However, in practice, the adoption of digital diabetes technologies is significantly uneven, with poorer countries lagging far behind wealthier nations in the use of pumps, continuous glucose monitors (CGMs), telemedicine, and AI tools. This disparity raises urgent questions regarding equity.These patterns reflect the well-known equity principles. In Tudor Hart's classic "inverse care law," new health innovations tend to reach affluent populations first, leaving high-need groups behind (7). In diabetes, this effect is amplified by a persistent digital divide; low-income and rural patients face financial, educational, and connectivity barriers to using CGMs, pumps, or telehealth, whereas wealthier patients rapidly adopt these tools (7,8). Moreover, data-driven tools risk algorithmic bias; AI models trained on data from well-resourced settings may misdiagnose or undertreat patients from marginalized communities (9). This dynamic is compounded by regulatory and contextual inequities; for example, technologies developed in high-income countries are often implemented in low-resource areas without local adaptation, a form of "digital colonialism' (9). Therefore, without paying attention to these systemic factors (inverse care law, digital access, biased algorithms, and uneven regulation), new diabetes technologies may inadvertently widen global disparities instead of closing them (7,9). Increasing evidence highlights this disparity. A 2025 JAMA Network study, which focused on pediatric diabetes care through the SWEET initiative, found that "rapid advancement in diabetes technologies has resulted in global disparities in terms of access" (10). High-income countries (HICs) now reimburse advanced systems, whereas low-and middle-income countries (LMICs) often limit access to basic glucometers or have no devices at all. Indeed, the WHO reports that "on a global level, 1 out of every 2 people needing insulin for T2D does not get this essential medicine" (11) and that insulin consumption in LMICs does not keep pace with the epidemic. In Europe alone, one analysis found that reimbursement policies for pumps and CGMs were highly heterogeneous, even among affluent countries (10), a microcosm of wider inequities. Globally, centers with full technology access achieve far lower HbA₁c levels than those with limited resources (10). Such data clarify that unequal access to technology translates into unequal health outcomes; countries still struggle with the basic issue of insulin availability, much less "closed-loop" artificial pancreas therapy (10).LMICs face significant challenges in terms of diabetes care. More than 80% of diabetes cases are now found in these regions ( 12), yet they often lack adequate screening and treatment infrastructure. For instance, diabetic eye care, where smartphone fundus cameras and AI grading could make a significant difference, is largely unavailable on a large scale; only one of the 50 LMICs has a national diabetic retinopathy screening program (12). A recent review of screening in South Asia and Africa found that community-based telemedicine and AI-enabled imaging improved coverage and cost-effectiveness, yet are still pilot efforts in resource-poor settings (12). Mobile health initiatives show promise ( 13), but such successes remain isolated and often depend on external funding or NGOs.Several factors have contributed to the digital divide (Table 1). Cost was one of the most significant factors. Advanced devices and software can be quite expensive; for example, a CGM sensor can cost hundreds of dollars in just a few weeks of use. Additionally, insulin pumps and AI-based diagnostic systems require expensive hardware and maintenance. Thus, out-of-pocket payments remain the norm in many countries (10). Additionally, reliable Internet and cellular connectivity, which many applications and telehealth tools require, are not widely available. In the US, both poor urban and rural populations have limited broadband access, and Internet connectivity is a significant social determinant of health for people with diabetes (8). In sub-Saharan Africa and South Asia, where smartphone ownership and data plans lag, simple mHealth programmes struggle to engage users.Beyond economics, health system readiness and regulations pose barriers. Many LMIC clinics lack trained staff to use or interpret digital data; as one survey noted, even adequate clinic staffing and multidisciplinary teams contribute greatly to outcomes (10). Physicians in underresourced health systems have little time to...
- 20 March 2026
- Published by Frontiers Media SA in Frontiers in Digital Health
- Vol. 8, 1783456
Open AccessTechnology-driven diabetes care: innovation without equity?
Diabetes mellitus type 1, commonly known as type 1 diabetes (T1D), is an autoimmune disease that occurs when the body's immune system destroys insulin-producing β-cells in the pancreas, leading to little or no endogenous insulin production (5). People with T1D (often diagnosed in childhood) require lifelong insulin therapy to remain alive (5). In contrast, Diabetes mellitus type 2, also commonly known as type 2 diabetes (T2D), is a form of diabetes mellitus characterized by insulin resistance and relative insulin deficiency (5). Most patients with T2D are initially managed with lifestyle changes and oral medications, with insulin reserved for later stages or in special situations. T2D is far more common than T1D, accounting for approximately 90-95% of all diabetes cases(5), and is strongly associated with obesity and aging.These distinctions affect technology use; advanced devices such as insulin pumps and automated "artificial pancreas" systems have been developed primarily for insulin-dependent patients, whereas T2D care more often uses glucose meters, CGMs, telemedicine, and mobile apps to support lifestyle and medication adherence. Notably, digital interventions have been shown to improve glycemic control in both T1 and T2Ds (6), but access and uptake have not been equal in the largely non-insulin-dependent T2 population.In theory, these advancements can reduce complications and costs. However, in practice, the adoption of digital diabetes technologies is significantly uneven, with poorer countries lagging far behind wealthier nations in the use of pumps, continuous glucose monitors (CGMs), telemedicine, and AI tools. This disparity raises urgent questions regarding equity.These patterns reflect the well-known equity principles. In Tudor Hart's classic "inverse care law," new health innovations tend to reach affluent populations first, leaving high-need groups behind (7). In diabetes, this effect is amplified by a persistent digital divide; low-income and rural patients face financial, educational, and connectivity barriers to using CGMs, pumps, or telehealth, whereas wealthier patients rapidly adopt these tools (7,8). Moreover, data-driven tools risk algorithmic bias; AI models trained on data from well-resourced settings may misdiagnose or undertreat patients from marginalized communities (9). This dynamic is compounded by regulatory and contextual inequities; for example, technologies developed in high-income countries are often implemented in low-resource areas without local adaptation, a form of "digital colonialism' (9). Therefore, without paying attention to these systemic factors (inverse care law, digital access, biased algorithms, and uneven regulation), new diabetes technologies may inadvertently widen global disparities instead of closing them (7,9). Increasing evidence highlights this disparity. A 2025 JAMA Network study, which focused on pediatric diabetes care through the SWEET initiative, found that "rapid advancement in diabetes technologies has resulted in global disparities in terms of access" (10). High-income countries (HICs) now reimburse advanced systems, whereas low-and middle-income countries (LMICs) often limit access to basic glucometers or have no devices at all. Indeed, the WHO reports that "on a global level, 1 out of every 2 people needing insulin for T2D does not get this essential medicine" (11) and that insulin consumption in LMICs does not keep pace with the epidemic. In Europe alone, one analysis found that reimbursement policies for pumps and CGMs were highly heterogeneous, even among affluent countries (10), a microcosm of wider inequities. Globally, centers with full technology access achieve far lower HbA₁c levels than those with limited resources (10). Such data clarify that unequal access to technology translates into unequal health outcomes; countries still struggle with the basic issue of insulin availability, much less "closed-loop" artificial pancreas therapy (10).LMICs face significant challenges in terms of diabetes care. More than 80% of diabetes cases are now found in these regions ( 12), yet they often lack adequate screening and treatment infrastructure. For instance, diabetic eye care, where smartphone fundus cameras and AI grading could make a significant difference, is largely unavailable on a large scale; only one of the 50 LMICs has a national diabetic retinopathy screening program (12). A recent review of screening in South Asia and Africa found that community-based telemedicine and AI-enabled imaging improved coverage and cost-effectiveness, yet are still pilot efforts in resource-poor settings (12). Mobile health initiatives show promise ( 13), but such successes remain isolated and often depend on external funding or NGOs.Several factors have contributed to the digital divide (Table 1). Cost was one of the most significant factors. Advanced devices and software can be quite expensive; for example, a CGM sensor can cost hundreds of dollars in just a few weeks of use. Additionally, insulin pumps and AI-based diagnostic systems require expensive hardware and maintenance. Thus, out-of-pocket payments remain the norm in many countries (10). Additionally, reliable Internet and cellular connectivity, which many applications and telehealth tools require, are not widely available. In the US, both poor urban and rural populations have limited broadband access, and Internet connectivity is a significant social determinant of health for people with diabetes (8). In sub-Saharan Africa and South Asia, where smartphone ownership and data plans lag, simple mHealth programmes struggle to engage users.Beyond economics, health system readiness and regulations pose barriers. Many LMIC clinics lack trained staff to use or interpret digital data; as one survey noted, even adequate clinic staffing and multidisciplinary teams contribute greatly to outcomes (10). Physicians in underresourced health systems have little time to...
- Open Access
- 4 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1) , 779
Correction: Emotional contagion, anxiety, and depression during COVID-19: a survey from Egypt
- 4 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1) , 779
Open AccessCorrection: Emotional contagion, anxiety, and depression during COVID-19: a survey from Egypt